These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 23921575)

  • 1. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
    Kang YK; Yook JH; Park YK; Lee JS; Kim YW; Kim JY; Ryu MH; Rha SY; Chung IJ; Kim IH; Oh SC; Park YS; Son T; Jung MR; Heo MH; Kim HK; Park C; Yoo CH; Choi JH; Zang DY; Jang YJ; Sul JY; Kim JG; Kim BS; Beom SH; Cho SH; Ryu SW; Kook MC; Ryoo BY; Kim HK; Yoo MW; Lee NS; Lee SH; Kim G; Lee Y; Lee JH; Noh SH
    J Clin Oncol; 2021 Sep; 39(26):2903-2913. PubMed ID: 34133211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
    Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
    Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma.
    Honma Y; Yamada Y; Terazawa T; Takashima A; Iwasa S; Kato K; Hamaguchi T; Shimada Y; Ohashi M; Morita S; Fukagawa T; Machida N; Katai H
    Surg Today; 2016 Sep; 46(9):1076-82. PubMed ID: 26563224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
    Newman E; Potmesil M; Ryan T; Marcus S; Hiotis S; Yee H; Norwood B; Wendell M; Muggia F; Hochster H
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S97-100. PubMed ID: 16399443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
    Spizzo G; Öfner D; de Vries A; Lukas P; Steger G; Pluschnig U; Zacherl J; Widder J; Zabernigg A; Gastl G; Mühlmann G
    Ann Surg Oncol; 2011 Mar; 18(3):677-83. PubMed ID: 21063792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of multimodality treatment: two and four courses of neoadjuvant chemotherapy using S-1/CDDP or S-1/CDDP/docetaxel followed by surgery and S-1 adjuvant chemotherapy for macroscopically resectable serosa-positive gastric cancer: a randomized phase II trial (COMPASS-D trial).
    Yoshikawa T; Taguri M; Sakuramoto S; Kunisaki C; Fukunaga T; Ito S; Cho H; Tanabe K; Nishikawa K; Matsui T; Morita S; Tsuburaya A
    Jpn J Clin Oncol; 2012 Jan; 42(1):74-7. PubMed ID: 22102736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction.
    Hosoda K; Azuma M; Katada C; Ishido K; Niihara M; Ushiku H; Sakuraya M; Washio M; Wada T; Watanabe A; Harada H; Tanabe S; Koizumi W; Yamashita K; Hiki N
    Int J Clin Oncol; 2020 Jun; 25(6):1090-1097. PubMed ID: 32124094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
    Tamura S; Fujitani K; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Furukawa H;
    Oncology; 2011; 80(5-6):296-300. PubMed ID: 21778769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).
    Heinrich K; Heinemann V; Stintzing S; Müller L; Ettrich TJ; Büchner-Steudel P; Geißler M; Trojan J; Moosmann N; Folprecht G; Schmidt J; Kanzler S; Kullmann F; Moulin JC; Werner J; Angele MK; Probst V; Held S; Schulz C; Boukovala M
    Oncol Res Treat; 2024; 47(6):251-261. PubMed ID: 38565089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer.
    Oki E; Emi Y; Kusumoto T; Sakaguchi Y; Yamamoto M; Sadanaga N; Shimokawa M; Yamanaka T; Saeki H; Morita M; Takahashi I; Hirabayashi N; Sakai K; Orita H; Aishima S; Kakeji Y; Yamaguchi K; Yoshida K; Baba H; Maehara Y
    Ann Surg Oncol; 2014 Jul; 21(7):2340-6. PubMed ID: 24604583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.
    Moehler M; Gockel I; Roessler HP; Arnold D; Trarbach T; Thomaidis T; Klautke G; Rödel C; Brenner B; Lang H; Galle PR; Schimanski CC; Schmidberger H
    BMC Cancer; 2013 Feb; 13():75. PubMed ID: 23394629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
    Zang DY; Yang DH; Kim MJ; Jang KM; Hwang SW; Yoo KS; Han T; Kim HY; Kim HJ; Kwon JH; Song HH; Park S; Jung JY; Kim HS; Kim JH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):877-83. PubMed ID: 19190908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
    Kosaka T; Akiyama H; Makino H; Takagawa R; Kimura J; Ono H; Kunisaki C; Endo I
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):281-5. PubMed ID: 24253176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.
    Iwatsuki M; Orita H; Kobayashi K; Hidaka S; Arigami T; Kusumoto T; Satake H; Oki E; Tsutsumi S; Tobimatsu K; Shimokawa M; Saeki H; Makiyama A; Baba H; Mori M
    Gastric Cancer; 2022 Jan; 25(1):180-187. PubMed ID: 34379229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
    Endo S; Terazawa T; Goto M; Tanaka R; Kato T; Fujitani K; Kawakami H; Sakai D; Kurokawa Y; Tsujinaka T; Shimokawa T; Satoh T
    BMC Cancer; 2022 Jul; 22(1):811. PubMed ID: 35870893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.